@phdthesis{oai:hama-med.repo.nii.ac.jp:00003000,
 author = {Hakamata, Akio},
 month = {Jan},
 note = {doctoral, 医学系研究科, To elucidate whether the pharmacokinetics (PK) and pharmacodynamics (PD) of sildenafil are influenced differently when it is coadministered with bosentan (S+B) or with ambrisentan (S+A), we evaluated the PK and PD profiles of sildenafil before and after 4-5 weeks of S+A or S+B treatment in patients with pulmonary arterial hypertension. The area under the plasma concentration-time curve of sildenafil was significantly higher in S+A treatment than in S+B treatment (165.8 ng･h/mL vs. 396.8 ng･h/mL, P=0.018) and the oral clearance of sildenafil was significantly lower after S+A treatment than after S+B treatment (120.6 L/h/kg vs. 50.4 L/h/kg, P=0.018). In the PD study, incremental shuttle walking distance was superior during treatment with S+A than during treatment with S+B (S+B; 280 m vs. S+A; 340 m, P=0.042). There were no concerns about safety with either combination therapy regime.},
 school = {浜松医科大学},
 title = {Pharmacokinetic and pharmacodynamic comparison of sildenafil-bosentan and sildenafil-ambrisentan combination therapies for pulmonary hypertension},
 year = {2016}
}